Markets
News
Analysis
User
24/7
Economic Calendar
Education
Data
- Names
- Latest
- Prev
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
A:--
F: --
A:--
F: --
P: --
A:--
F: --
P: --
A:--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
--
F: --
P: --
No matching data
Latest Views
Latest Views
Trending Topics
To quickly learn market dynamics and follow market focuses in 15 min.
In the world of mankind, there will not be a statement without any position, nor a remark without any purpose.
Inflation, exchange rates, and the economy shape the policy decisions of central banks; the attitudes and words of central bank officials also influence the actions of market traders.
Money makes the world go round and currency is a permanent commodity. The forex market is full of surprises and expectations.
Top Columnists
Enjoy exciting activities, right here at FastBull.
The latest breaking news and the global financial events.
I have 5 years of experience in financial analysis, especially in aspects of macro developments and medium and long-term trend judgment. My focus is maily on the developments of the Middle East, emerging markets, coal, wheat and other agricultural products.
BeingTrader chief Trading Coach & Speaker, 8+ years of experience in the forex market trading mainly XAUUSD, EUR/USD, GBP/USD, USD/JPY, and Crude Oil. A confident trader and analyst who aims to explore various opportunities and guide investors in the market. As an analyst I am looking to enhance the trader’s experience by supporting them with sufficient data and signals.
Latest Update
Risk Warning on Trading HK Stocks
Despite Hong Kong's robust legal and regulatory framework, its stock market still faces unique risks and challenges, such as currency fluctuations due to the Hong Kong dollar's peg to the US dollar and the impact of mainland China's policy changes and economic conditions on Hong Kong stocks.
HK Stock Trading Fees and Taxation
Trading costs in the Hong Kong stock market include transaction fees, stamp duty, settlement charges, and currency conversion fees for foreign investors. Additionally, taxes may apply based on local regulations.
HK Non-Essential Consumer Goods Industry
The Hong Kong stock market encompasses non-essential consumption sectors like automotive, education, tourism, catering, and apparel. Of the 643 listed companies, 35% are mainland Chinese, making up 65% of the total market capitalization. Thus, it's heavily influenced by the Chinese economy.
HK Real Estate Industry
In recent years, the real estate and construction sector's share in the Hong Kong stock index has notably decreased. Nevertheless, as of 2022, it retains around 10% market share, covering real estate development, construction engineering, investment, and property management.
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
View All
No data
Not Logged In
Log in to access more features
FastBull Membership
Not yet
Purchase
Log In
Sign Up
Hongkong, China
Ho Chi Minh, Vietnam
Dubai, UAE
Lagos, Nigeria
Cairo, Egypt
White Label
Data API
Web Plug-ins
Affiliate Program
If you're interested in broad exposure to the Healthcare - Biotech segment of the equity market, look no further than the Invesco Biotechnology & Genome ETF (PBE), a passively managed exchange traded fund launched on 06/23/2005.
Retail and institutional investors increasingly turn to passively managed ETFs because they offer low costs, transparency, flexibility, and tax efficiency; these kind of funds are also excellent vehicles for long term investors.
Investor-friendly, sector ETFs provide many options to gain low risk and diversified exposure to a broad group of companies in particular sectors. Healthcare - Biotech is one of the 16 broad Zacks sectors within the Zacks Industry classification. It is currently ranked 5, placing it in top 31%.
Index Details
The fund is sponsored by Invesco. It has amassed assets over $271.87 million, making it one of the average sized ETFs attempting to match the performance of the Healthcare - Biotech segment of the equity market. PBE seeks to match the performance of the Dynamic Biotechnology & Genome Intellidex Index before fees and expenses.
The Dynamic Biotech & Genome Intellidex Index seeks to provide capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including price momentum, earnings momentum, quality, management action, and value.
Costs
Cost is an important factor in selecting the right ETF, and cheaper funds can significantly outperform their more expensive counterparts if all other fundamentals are the same.
Annual operating expenses for this ETF are 0.58%, making it on par with most peer products in the space.
It has a 12-month trailing dividend yield of 0.05%.
Sector Exposure and Top Holdings
Even though ETFs offer diversified exposure that minimizes single stock risk, investors should also look at the actual holdings inside the fund. Luckily, most ETFs are very transparent products that disclose their holdings on a daily basis.
This ETF has heaviest allocation in the Healthcare sector--about 99.90% of the portfolio.
Looking at individual holdings, Gilead Sciences Inc (GILD) accounts for about 5.58% of total assets, followed by Illumina Inc (ILMN) and Regeneron Pharmaceuticals Inc (REGN).
The top 10 holdings account for about 48.18% of total assets under management.
Performance and Risk
So far this year, PBE return is roughly 8.14%, and was up about 20.51% in the last one year (as of 09/18/2024). During this past 52-week period, the fund has traded between $52.52 and $71.87.
The ETF has a beta of 0.80 and standard deviation of 23.55% for the trailing three-year period, making it a high risk choice in the space. With about 32 holdings, it has more concentrated exposure than peers.
Alternatives
Invesco Biotechnology & Genome ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. Thus, PBE is a sufficient option for those seeking exposure to the Health Care ETFs area of the market. Investors might also want to consider some other ETF options in the space.
SPDR S&P Biotech ETF (XBI) tracks S&P Biotechnology Select Industry Index and the iShares Biotechnology ETF (IBB) tracks Nasdaq Biotechnology Index. SPDR S&P Biotech ETF has $7.70 billion in assets, iShares Biotechnology ETF has $7.73 billion. XBI has an expense ratio of 0.35% and IBB charges 0.45%.
Bottom Line
To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center.
Zacks Investment Research
Gilead Sciences (GILD) closed at $83.08 in the latest trading session, marking a -0.1% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.03%. Meanwhile, the Dow lost 0.04%, and the Nasdaq, a tech-heavy index, added 0.2%.
The HIV and hepatitis C drugmaker's stock has climbed by 11.7% in the past month, exceeding the Medical sector's gain of 2.67% and the S&P 500's gain of 1.54%.
The investment community will be paying close attention to the earnings performance of Gilead Sciences in its upcoming release. The company is expected to report EPS of $1.66, down 27.51% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $6.98 billion, showing a 0.98% drop compared to the year-ago quarter.
GILD's full-year Zacks Consensus Estimates are calling for earnings of $3.78 per share and revenue of $27.63 billion. These results would represent year-over-year changes of -43.75% and +1.9%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for Gilead Sciences. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 0.04% higher. Currently, Gilead Sciences is carrying a Zacks Rank of #3 (Hold).
Looking at valuation, Gilead Sciences is presently trading at a Forward P/E ratio of 22.01. Its industry sports an average Forward P/E of 23.02, so one might conclude that Gilead Sciences is trading at a discount comparatively.
We can additionally observe that GILD currently boasts a PEG ratio of 2.88. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. GILD's industry had an average PEG ratio of 2.28 as of yesterday's close.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 79, putting it in the top 32% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Zacks Investment Research
Shares of Ascendis Pharma ASND rose 17% on Monday after it reported top-line results from the pivotal ApproaCH study that evaluated investigational once-weekly administered TransCon CNP in children aged two to 11 years with achondroplasia, the most common form of dwarfism.
ASND Drug Shows AGV Benefit in Achondroplasia Patients
The ApproaCH study met its primary endpoint of annualized growth velocity (AGV) at 52 weeks — children treated with TransCon CNP achieved a mean AGV of 5.89 cm/year compared with 4.41 cm/year in the placebo group.
Management also provided sub-group analyses of this data by age groups — children aged two to less than five years and another group aged five to 11 years. Patients in the first group who received TransCon CNP achieved a mean AGV of 6.07 cm/year compared with 5.06 cm/year in placebo. Those who received the drug in the second age group achieved a mean AGV of 5.79 cm/year compared with 4.02 cm/year on placebo.
Per Ascendis, treatment with the drug also demonstrated statistically significant improvement in other secondary endpoints, including height Z-score and changing from baseline AGV.
But Why Did BioMarin Stock Dip on TransCon CNP Data
There is only one drug approved to treat achondroplasia in the United States and Europe — Voxzogo — which is marketed by BioMarin BMRN. Since its launch in 2021, BMRN has been experiencing a rapid uptake for Voxzogo driven by strong prescription demand. The drug added nearly $337 million to BioMarin’s topline in the first half of 2024, up 67% year over year.
While it is difficult to compare the results of two different clinical studies directly, investors were likely impressed with the once-weekly dosing advantage of TransCon CNP over Voxzogo, which requires daily dosing. This major factor was not only responsible for Ascendis’ share price soaring but also sent BioMarin stock down nearly 18% after the results were announced.
Ascendis’ shares have moved up 10.8% in the year compared with the industry’s 1.0% growth.
Ascendis’ Future Plans for the Drug
Based on the ApproaCH study results, management intends to submit a regulatory filing seeking approval for TransCon CNP in achondroplasia with the FDA during first-quarter 2025. It also plans to submit a similar filing with the EMA by third-quarter 2025.
ASND’s Zacks Ranks
Ascendis currently carries a Zacks Rank #3 (Hold).
Ascendis Pharma A/S Price
Ascendis Pharma A/S price | Ascendis Pharma A/S Quote
Our Key Picks in the Biotech Sector
Some better-ranked stocks in the overall healthcare sector are Bioventus BVS and Illumina ILMN. Each stock presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Bioventus’ 2024 earnings per share (EPS) have risen from 27 cents to 40 cents. Estimates for 2025 have increased from 43 cents to 45 cents during the same period. Year to date, shares of Bioventus have surged 109.9%.
BVS’ earnings beat estimates in three of the last four quarters and missed the mark on one occasion. Bioventus delivered a four-quarter average earnings surprise of 102.86%.
In the past 60 days, estimates for Illumina’s 2024 EPS have risen from $1.84 to $3.62. Estimates for 2025 have increased from $3.22 to $4.43 during the same period. Year to date, Illumina’s shares have lost 7.0%.
Earnings of Illumina beat estimates in each of the last four quarters. Illumina delivered a four-quarter average earnings surprise of 463.46%.
Zacks Investment Research
NORTHAMPTON, MA / ACCESSWIRE / September 17, 2024 / IlluminaThe quality control stability scientist embraces family, sports, work, and her leadership role in Illumina's iLatinx employee resource group
Originally published on Illumina News Center
Karina Katalina Moreno has taken a circuitous route to her American dream. She grew up in Monterrey, Mexico, about 140 miles (225 km) south of Laredo, Texas, and got her degree in biotech engineering at Tecnológico de Monterrey. Following a brief stop in Barcelona, Spain, she earned her master of science degree at the University of Edinburgh.
Family brought Moreno back to Monterrey. Her mother was diagnosed with lung cancer, and she moved in to help care for her parents and three siblings. She worked as a science teacher at a local high school and helped her mom get to and from treatment.
"After my mom passed away, I thought, okay, this is life, I knew it was coming," she says. "She was diagnosed with stage three lung cancer, and the doctors told us she wouldn't have a lot of time. She was a real fighter, and stayed with us for three more years. But 13 days after my mom died, my dad passed from COVID. At that point I felt lost. My life changed so much in two weeks that I didn't know what I was going to do with my life."
Coming to Illumina Moreno had worked in pharma and cosmetics but always wanted to pursue a career in biotech. In 2023, a friend encouraged her to apply at Illumina and, after a rigorous interview process, she was hired as a quality control stability scientist. In this role, she focuses on measuring reagent stability, which has already paid big dividends in extended expiration dates.
She's been with Illumina for about a year and a half, but Moreno is already making her mark. She is well known in Building 6, at Illumina's San Diego campus, for her seemingly endless supply of Mexican candy-it's part of her ongoing mission to share her culture.
iLatinx Moreno is the treasurer of iLatinx, a growing employee resource group (ERG) at Illumina. The group has more than a hundred active members and hosts many events that focus on building community: attending San Diego Padres and Wave games, celebrating Hispanic Heritage Month, and working with the Make-a-Wish Foundation and the Clearity Foundation.
The group has also committed to mentoring young women. For the past two summers, iLatinx has partnered with the Women at Illumina Network ERG to sponsor Girls Who Lead days at the company.
"We have around 60 girls who come to Illumina and go to the lab with us," Moreno says, "but we try to involve them in other activities, as well, because not everyone works in the lab. Some people handle money or are in charge of production. We want to show them all their options."
The iLatinx group has big plans for this year's Hispanic Heritage Month, which runs from September 15 to October 15: a career panel, salsa classes, a mariachi band, and lots of treats. They highlight different countries each year: Last time it was Mexico and Peru; this year will be Colombia and Venezuela, among others.
"People like to learn about the different cultures at Illumina, and we try to find people from those places who can share their flags, food, and local customs," Moreno says. "We want everyone to know they don't have to be Latino to be part of this community. They only need to like the food, music, and culture."
Her safe space An avid athlete, Moreno has been active in team handball since she was young and now plays on teams in San Diego and Baja California. At Illumina, she participates in flag football, basketball, and softball. When she's not working or playing, she often visits her family in Monterrey. But looking at the life she's built, she is incredibly grateful to have found a home in San Diego and Illumina.
"Everybody is really open [at Illumina], and that makes me feel great," says Moreno. "I have this accent and nobody cares, and I can wear a flower shirt, which is typical in Mexico, or sing in Spanish, and nobody is going to say anything. For me, it's a really safe space."
Karina Katalina Moreno at the Paris Olympics, summer 2024. | Photo courtesy of Moreno.
View additional multimedia and more ESG storytelling from Illumina on 3blmedia.com.
Contact Info: Spokesperson: Illumina Website: https://www.3blmedia.com/profiles/illumina Email: info@3blmedia.com
SOURCE: Illumina
View the original press release on accesswire.comShares of NuCana plc NCNA skyrocketed 150.8% on Monday after the announcement of encouraging final data from the mid-stage study of its investigational candidate, NUC-7738, in combination with Merck’s MRK blockbuster oncology drug, Keytruda (pembrolizumab), to treat metastatic melanoma. The melanoma patient population included those who were refractory to or had relapsed on prior PD-1 inhibitor therapy.
The results were presented at the ESMO Congress held on Sept. 14, 2024, in Spain.
NCNA Combo Therapy Shows Superior Efficacy in Melanoma Study
Per the data readout from the phase II NuTide:701 study, out of the 12 patients treated with the NUC-7738/Meck’s Keytruda combo regimen, nine (75%) achieved disease control, including two patients who achieved partial responses.
A patient who had previously undergone two rounds of PD-1 inhibitor therapy and experienced disease progression within two months after treatment with Bristol Myers’ BMY Yervoy (ipilimumab) and Opdivo (nivolumab), achieved a 55% reduction in tumor size. Additionally, seven out of the 12 patients had a progression-free survival exceeding five months, which is unusually long for this group. Per NuCana, the median progression-free survival duration with the standard-of-care treatment for PD-1 inhibitor refractory and resistant melanoma patients is 2-3 months.
In the NuTide:701 study, the combination of NUC-7738 and Meck’s Keytruda also demonstrated a favorable safety profile.
NUC-7738 is a novel anti-cancer agent that disrupts RNA polyadenylation. Its unique mechanism of action allows the candidate to sensitize PD-1-resistant tumors to rechallenge with PD-1 inhibitors. Per the company, the data presented from tumor biopsies obtained before and after NUC-7738-based treatment demonstrated increases in genes related to antigen presentation and T-cell activation, which supports the hypothesis.
Year to date, shares of NuCana have lost 13.9% against the industry’s 0.5% growth.
Bristol Myer’s immunotherapy drug, Opdivo, in combination with Yervoy, is indicated for the treatment of adult and pediatric patients of 12 years and older with unresectable or metastatic melanoma. Both drugs are individually approved for the melanoma indication. Bristol Myer is also currently conducting studies to further expand the combo’s label. Bristol Myer’s Opdivo is approved both as a monotherapy and in combination with Yervoy to treat several other cancer indications in many countries, including the United States and the EU.
Like Bristol Myers’ Opdivo, Merck’s Keytruda is also an anti-PD-1 therapy. It is currently marketed as the standard of care in the frontline treatment of metastatic non-small cell lung cancer patients. Merck’s Keytruda is approved for several types of cancer, accounting alone for 47% of the company’s pharmaceutical sales in 2023. Keytruda is continuously growing and expanding into new indications and markets globally, bolstering Merck’s position in the oncology market.
NuCana’s Future Plans for NUC-7738 Clinical Development
Based on additional data on NUC-7738 obtained in other tumor types, NuCana believes that the unique mechanism of action of the candidate is not restricted to melanoma and that NUC-7738 could potentially sensitize other PD-1 inhibitor-resistant tumor types.
The company expects to share further development plans for NUC-7738 soon.
NuCana PLC Sponsored ADR Price and Consensus
NuCana PLC Sponsored ADR price-consensus-chart | NuCana PLC Sponsored ADR Quote
NuCana’s Other Pipeline Developmental Programs
Apart from NUC-7738, NuCana’s clinical pipeline has another investigational candidate, NUC-3373, which is currently being evaluated in combination with other agents in three separate early to mid-stage studies to treat colorectal cancer, lung cancer and advanced solid tumors.
Data readouts from all three studies are expected by the end of 2024.
Zacks Rank & Stock to Consider
NuCana currently carries a Zacks Rank #3 (Hold).
A better-ranked stock in the biotech sector is Illumina, Inc. ILMN, sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Illumina’s 2024 earnings per share have moved up from $1.84 to $3.62. The consensus estimate for 2025 earnings has improved from $3.22 to $4.43. Year to date, shares of ILMN have lost 7%.
ILMN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 463.46%.
Zacks Investment Research
Shares of Zentalis Pharmaceuticals ZNTL gained 13.6% on Monday after it announced that the FDA has lifted the partial clinical hold previously imposed on three studies of the company’s lead product candidate, azenosertib, for three different cancer indications. The decision was based on the regulatory body’s review of Zentalis’ complete response package, which included a comprehensive safety assessment of the azenosertib program.
Zentalis’ azenosertib, a potentially first-in-class oral WEE1 inhibitor, is currently being studied as a monotherapy and in combination with other therapies for treating different types of cancer indications, including solid tumors and ovarian cancer.
Per Zentalis, the FDA has given the green light to resume enrollment in all ongoing azenosertib clinical studies with no changes in the clinical development plan. The company is gearing up to resume study activities across the azenosertib development program at the earliest.
Year to date, shares of Zentalis have plunged 75.7% against the industry’s 0.5% growth.
Developmental Setbacks Faced by ZNTL for Azenosertib
In June 2024, the FDA placed a partial clinical hold on the following azenosertib studies — the phase I ZN-c3-001 dose-escalation for solid tumors, the phase II ZN-c3-005 DENALI study for platinum-resistant ovarian cancer (PROC) and the phase II ZN-c3-004 TETON study for uterine serous carcinoma.
This action was taken by the regulatory body after two patients in the DENALI study died due to presumed sepsis. This resulted in a huge dip in Zentalis’ share price back then.
In its second-quarter earnings release, Zentalis announced that it has discontinued the development of the combination of its BCL-2 inhibitor, ZN-d5, with azenosertib due to unsatisfactory efficacy data. The combo therapy was evaluated in a phase I study for the treatment of relapsed or refractory acute myeloid leukemia.
ZNTL’s Future Clinical Development Plan for Azenosertib
ZNTL has already completed enrollment in cohort 1b of the DENALI study. Overall efficacy and safety data from the same is expected to be announced later in 2024. Zentalis also plans to present data from the ZN-c3-001 and the MAMMOTH studies later in the ongoing year.
The phase I/II MAMMOTH (ZN-c3-006) study is evaluating azenosertib in combination with GSK’s GSK PARP inhibitor Zejula (niraparib) and azenosertib as monotherapy for treating PROC.
The study is being conducted in partnership with GSK.
GSK’s Zejula is already approved for ovarian cancer and is currently being studied for additional ovarian cancer stages as well as non-small cell lung cancer and endometrial cancer.
Per the latest press release, Zentalis is scheduled to present azenosertib monotherapy data and provide additional updates on the azenosertib clinical development program and other data presentation timelines at an upcoming medical conference.
Zentalis Pharmaceuticals, Inc. Price and Consensus
Zentalis Pharmaceuticals, Inc. price-consensus-chart | Zentalis Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Zentalis currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Illumina, Inc. ILMN and Fulcrum Therapeutics, Inc. FULC, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Illumina’s 2024 earnings per share have moved up from $1.84 to $3.62. The consensus estimate for 2025 earnings has improved from $3.22 to $4.43. Year to date, shares of ILMN have lost 7%.
ILMN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 463.46%.
In the past 60 days, estimates for Fulcrum Therapeutics’ 2024 loss per share have narrowed from $1.24 to 33 cents. The consensus estimate for 2025 loss per share has narrowed from $1.71 to $1.14. Year to date, shares of FULC have plunged 52.9%.
FULC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 393.18%.
Zacks Investment Research
White Label
Data API
Web Plug-ins
Poster Maker
Affiliate Program
The risk of loss in trading financial instruments such as stocks, FX, commodities, futures, bonds, ETFs and crypto can be substantial. You may sustain a total loss of the funds that you deposit with your broker. Therefore, you should carefully consider whether such trading is suitable for you in light of your circumstances and financial resources.
No decision to invest should be made without thoroughly conducting due diligence by yourself or consulting with your financial advisors. Our web content might not suit you since we don't know your financial conditions and investment needs. Our financial information might have latency or contain inaccuracy, so you should be fully responsible for any of your trading and investment decisions. The company will not be responsible for your capital loss.
Without getting permission from the website, you are not allowed to copy the website's graphics, texts, or trademarks. Intellectual property rights in the content or data incorporated into this website belong to its providers and exchange merchants.